Derm In-Review Advisory Council Member, Dr. Ramya Kollipara, searched the journals so that you don’t have to! She reports on important take-aways from different dermatology journals for the months of October, November, and December of 2018.
It is key to keep in mind that “important” is subjective and what is contained in this review is one person’s view of what should be remembered from these months of the literature.
Best of October 2018
Kridin et al. JAMA Dermatol 2018; 154(10):1152-58.
DPP-4 inhibitor (especially vildagliptin over linagliptin) use was associated a 3-fold increased risk of BP. These patients had a higher rate of mucosal involvement and lower mean peripheral eosiniphil counts. Clinical improvement in BP was noted after discontinuation of DPP-4 inhibitors and should be considered in patients with BP on these medications.
Wolstencroft et al. JAMA Dermatol 2018;154(10):1199-1203.
Patients with dermatomyositis with anti-small ubiquitinlike modifier 1 activating enzyme antibodies are at increased risk of developing hydroxychloroquine-associated skin eruption due to differences in disease mechanisms between different autoantibody groups. No other dermatomyositis autoantibody subset had a positive or negative associated with skin eruption associated with hydroxychloroquine.
Clinically amelanotic or hypomelanotic melanoma: Anatomic distribution, risk factors, and survival.
Wee at al. JAAD 2018; 79(4):645-651.
Skin phototype 1, red or blond hair color, actinic keratosis, nodular, desmoplastic and LM subtype, increased Breslow thickness and increased mitoses were independently associated with amelanotic or hypomelanotic melanoma. The face, ears, lateral aspect of the neck, upper arm, posterior forearm, dorsal hand, anterior lower leg were associated with increased odds of amelanotic or hypomelanotic melanoma compared to the upper back. Mortality was higher for amelanotic or hypomelanotic melanoma than for pigmented melanoma but then was similar when Breslow thickness was taken into account.
Best of November 2018
Asdigian et al. JAMA Dermatol 2018;154(11):1272-80.
Nevus accumulation increased linearly over time. Hispanic and nonhispanic white boys accumulated nevi at a faster rate than girls. Girls accumulated more nevi on body areas intermittently exposed to the skin. New nevi appearance plateaued on sites chronically exposed to the skin in both boys and girls by age 16 years.
Jull et al. JAMA Dermatol 2018;154(11):1304-1311.
Adding exercise to compression for venous leg ulcers increased healing rates. The biggest improvement was seen with progressive resistance exercise plus physical therapy in addition to compression.
Mangold et al. JAAD 2018;79(5):913-920.
Paraneoplatic GA is rare and 4/7 cases in the case-control study were associated with lung cancer. Histologically and clinically, paraneoplastic and classic GA were similar. Paraneoplastic GA was more likely to be generalized, refractory to treatment, and had perivascular inflammatory cells on histology.
Pregnancy outcomes in patients with vitiligo: A nationwide population-based cohort study from Korea.
Park et al. JAAD 2018;79(5):836-842.
Retrospective cohort study of 4738 pregnancies in women with vitiligo with age-matched controls without vitiligo. Patients with vitiligo had a lower live birth rate and a higher incidence of spontaneous abortion.
Best of December 2018
Kim et al. JAMA Dermatol 2018;154(12):1401-1408.
Multicenter cohort study of 467 moderately dysplastic nevi with clear clinical margins but positive histologic margins found no cases of cutaneous melanoma at biopsy site. Follow up was 6.9 years. Patients with 2 or more biopsied dysplastic nevi had an increased risk of developing melanoma at a separate site.
CADM1 is a diagnostic marker in early-stage mycosis fungoides: Multicenter study of 58 cases.
Yuki et al. JAAD 208;79(6):1039-46.
Cell-adhesion molecule 1 gene (CADM1) is a tumor suppressor gene and in this retrospective study immunohistochemical staining with CADM1 was done on MF and inflammatory skin disorder samples. 95% of MF samples were positive for CADM1 while none of the inflammatory skin disease samples were positive. CADM-1 positive cells can be seen in early MF when there are fewer infiltrating cells and may be a useful early diagnostic marker.
Li et al. JAAD 2018; 79(6):1101-1108.
67% of patients with history of tanning bed use had their second primary melanoma diagnosed at the time of or within 1 year of their original diagnosis versus only 28% of nontanners. Median time to diagnosis of the second primary in tanners was 225 days versus 3.5 years in non-tanners.
BONUS PICKS FROM THE JDD
Hand-picked by Dr. Adam Friedman, Senior Editor of Derm-In Review (part of ODAC’s “Journal of Drugs in Dermatology (JDD): A Year in Review” lecture)
October
Efficacy of Systemic Dapsone Treatment for Pyoderma Gangrenosum: A Retrospective Review
Din et al. JDD 17.10 (2018): 1058-1060.
- 27 patients – adjunctive tx
- 15.6% complete healing
- 81.3% partial improvement
- 3.1% demonstrated no response
- 3.7% requiring cessation of dapsonetherapy due to AE (MetHb)
Epidemiology of Skin Diseases in a Diverse Patient Population
Gaulding et al. JDD 17.10 (2018): 1032-1036.
- 65969 new dermatology patient visits
- 37% (n = 24086) black/African American
- 4% (n = 2776) Asian
- 0.4% (n = 260) Native American
- 7% (n = 4538) other
- Follicular disorders occurred with an increased frequency in Type V skin.
- Socioeconomic status (SES) impact
- Eczema or dermatitis was the most frequently encountered lowest
November
Wu et al. JDD 17.11 (2018): 1211-1218
-
- Infection was the most frequent (28.7%–41.8%).
- ADA, ETN, and UST were associated with a lower risk of infections then conventional tx (aHR: 0.93, 0.92, and 0.86, respectively, all P < 0.05).
- ADA was associated with a lower risk of malignancies (aHR: 0.71, P less than 0.05)
- ETN was associated with a lower risk of respiratory disease (aHR: 0.80, P < 0.05).
- Biologic therapies were associated with similar or lower risk then the oldie but goodies
- Infection was the most frequent (28.7%–41.8%).
December
Feldman et al. JDD 17.12 (2018): 1298-1308
-
- 740 PsO patients and 1411 non-PsO controls
- GI signs and symptoms assessed:
- Belly pain
- Feeling full/bloated
- Diarrhea
- Mucus in stool
- Blood in stool
- Unintentional weight loss
- All 6 were more prevalent in PsO patients compared with non-PsO controls.
- 740 PsO patients and 1411 non-PsO controls
Did you enjoy this Journal Review Series? Find previous ones here.
